Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment-Reference-Cited by-同舟云学术

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

Published:2016-05-15 Issue:8 Volume:30 Page:1229-1238
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Stellbrink Hans-Jürgen,Le Fevre Eric,Carr Andrew,Saag Michael S.,Mukwaya Geoffrey,Nozza Silvia,Valluri Srinivas Rao,Vourvahis Manoli,Rinehart Alex R.,McFadyen Lynn,Fichtenbaum Carl,Clark Andrew,Craig Charles,Fang Annie F.,Heera Jayvant

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference35 articles.

1. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International AIDS Society-USA panel;Thompson;JAMA,2012

2. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway;Brinkman;AIDS,1998

3. Managing issues related to antiretroviral therapy;Lesho;Am Fam Phys,2003

4. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics;Nolan;Expert Opin Drug Saf,2005

5. Class-sparing regimens for initial treatment of HIV-1 infection;Riddler;N Engl J Med,2008

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells;Scientific Reports;2024-06-17

2. Human Immunodeficiency Virus-1 Drug Resistance Mutations in Iranian Treatment-experienced Individuals;Current HIV Research;2024-01

3. Two-drug antiretroviral regimens for HIV;BMJ;2023-09-01

4. Relapse of neurosymptomatic cerebrospinal fluid HIV RNA escape;HIV Medicine;2023-07-24

5. Investigational drugs for HIV: trends, opportunities and key players;Expert Opinion on Investigational Drugs;2023-02-01